Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 6/20 | 1.00 |
| ▸ | PRKCG | P05129 | 5/20 | 1.00 |
| ▸ | PRKCB | P05771 | 5/20 | 1.00 |
| ▸ | PRKCH | P24723 | 5/20 | 1.00 |
| ▸ | PRKCE | Q02156 | 5/20 | 1.00 |
| ▸ | PRKCQ | Q04759 | 5/20 | 1.00 |
| ▸ | PRKCD | Q05655 | 5/20 | 1.00 |
| ▸ | PRKD3 | O94806 | 4/20 | 1.00 |
| ▸ | PRKCI | P41743 | 4/20 | 1.00 |
| ▸ | PRKCZ | Q05513 | 4/20 | 1.00 |
| ▸ | PRKD1 | Q15139 | 4/20 | 1.00 |
| ▸ | VAV1 | P15498 | 2/20 | 1.00 |
| ▸ | USP2 | O75604 | 2/20 | 0.80 |
| ▸ | TP53 | P04637 | 2/20 | 0.80 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.80 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.80 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.80 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.80 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.80 |
| ▸ | TSHR | P16473 | 1/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26309957 | 1.00 | PRKCA (1.00) | PRKCAPRKCGPRKCBPRKCHPRKCE | |
| SCHEMBL29366787 | 1.00 | PRKCA (1.00) | PRKCAPRKCGPRKCBPRKCHPRKCE | |
| SCHEMBL8750573 | 1.00 | PRKCA (1.00) | PRKCAPRKCGPRKCBPRKCHPRKCE | |
| SCHEMBL2411275 | 0.94 | PRKCA (0.95) | PRKCAPRKCGPRKCBPRKCHPRKCE | |
| SCHEMBL18399995 | 0.94 | PRKCA (0.95) | PRKCAPRKCGPRKCBPRKCHPRKCE | |
| SCHEMBL31109155 | 0.94 | PRKCA (0.95) | PRKCAPRKCGPRKCBPRKCHPRKCE | |
| SCHEMBL295345 | 0.94 | PRKCA (0.94) | PRKCAPRKCGPRKCBPRKCHPRKCE | |
| SCHEMBL29353576 | 0.94 | PRKCA (0.94) | PRKCAPRKCGPRKCBPRKCHPRKCE | |
| SCHEMBL1568997 | 0.94 | PRKCA (0.94) | PRKCAPRKCGPRKCBPRKCHPRKCE | |
| SCHEMBL3211990 | 0.94 | PRKCA (0.94) | PRKCAPRKCGPRKCBPRKCHPRKCE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1205 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260041660-A1 | Compositions And Methods for Treating Acute Respiratory Distress Syndrome (ARDS) And Inflammatory Disorders Caused by Corona Viruses and Other Respiratory Pathogens or Agents That Mediate Pulmonary Injury, Inflammation or Acute Respiratory Distress, And Related Compositions and Methods for Treating and Preventing Human SARS Coronavirus Infection, COVID-19 Disease and Related Symptoms | CHANG RICHARD L (US) | 2026-02-12 | — | — | US | claimed |
| US-12539289-B2 | Phorbol ester compositions and methods of use for treating or reducing the duration of cytopenia | BIOSUCCESS BIOTECH COMPANY, LIMITED (US) | 2026-02-03 | — | — | US | claimed |
| WO-2025235403-A1 | DIFFERENTIATION OF PANCREATIC ISLET CELLS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-11-13 | — | — | WO | claimed |
| US-20250332115-A1 | CONTROLLED EXPRESSION OF THERAPEUTICALLY RELEVANT BIOMOLECULES FOR LUMEN-LOCALIZED PAYLOADS IN BIOMIMETIC NANOVESICLES AND EXOSOMES | MALCOLM THOMAS (US) | 2025-10-30 | — | — | US | claimed |
| WO-2025072196-A1 | METHODS FOR CULTURING AND ASSAYING B CELL LYMPHOCYTES | BRUKER CELLULAR ANALYSIS, INC. (US) | 2025-04-03 | — | — | WO | claimed |
| EP-2804601-B1 | PHORBOL ESTER compounds for use in the treatment of neoplastic diseases | BIOSUCCESS BIOTECH CO LTD (US) | 2025-04-02 | — | — | EP | claimed |
| US-20250092360-A1 | METHODS AND COMPOSITIONS FOR GENERATING SOMATOSTATIN+ INTERNEURONS FROM HUMAN FOREBRAIN NEURAL PROGENITOR CELLS | TRAILHEAD BIOSYSTEMS INC. | 2025-03-20 | — | — | US | claimed |
| US-20240382532-A1 | STEM CELL DERIVED PANCREATIC ISLET DIFFERENTIATION | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-11-21 | — | — | US | claimed |
| US-20240358767-A1 | STEM CELL DIFFERENTIATION AND CHEMICAL COMPOUNDS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-10-31 | — | — | US | claimed |
| US-20240294879-A1 | STEM CELL DIFFERENTIATION AND POLYMERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-09-05 | — | — | US | claimed |
| WO-1997020212-A1 | TREATMENT OF INFLAMMATION BY INHIBITION OF LIPID BODY FORMATION | BETH ISRAEL DEACONESS MEDICAL CENTER (US) | 1997-06-05 | — | — | WO | claimed |
| EP-0457295-B1 | Use of a modulator of protein phosphorylation in the treatment of amyloidosis associated with Alzheimer's disease | UNIV ROCKEFELLER (US) | 1997-04-09 | — | — | EP | claimed |
| EP-0752867-A1 | SELECTIVE CELL PROLIFERATION | HEMOSOL INC. (CA) | 1997-01-15 | — | — | EP | claimed |
| US-5385915-A | Using an enzyme inhibitor | THE ROCKEFELLER UNIVERSITY (US) | 1995-01-31 | — | — | US | claimed |
| WO-1994016715-A1 | SELECTIVE CELL PROLIFERATION | HEMOSOL, INC. (CA) | 1994-08-04 | — | — | WO | claimed |
| EP-0457295-A2 | Use of a modulator of protein phosphorylation in the treatment of amyloidosis associated with Alzheimer's disease | THE ROCKEFELLER UNIVERSITY (US) | 1991-11-21 | — | — | EP | claimed |
| EP-0291728-A2 | Production of immune interferon and its mRNA | MELOY LABORATORIES, INC. (US) | 1988-11-23 | — | — | EP | claimed |
| EP-0139878-A2 | Production of immune interferon and its mRNA | MELOY LABORATORIES, INC. (US) | 1985-05-08 | — | — | EP | claimed |
| EP-0137691-A1 | Production of immune interferon and its mRNA | MELOY LABORATORIES, INC. (US) | 1985-04-17 | — | — | EP | claimed |
| EP-0063482-A2 | Production of immune interferon and its mRNA | MELOY LABORATORIES, INC. (US) | 1982-10-27 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240382532-A1 | STEM CELL DERIVED PANCREATIC ISLET DIFFERENTIATION | IAPP, PNLIP, ALPG | PRKCA 53/4885PRKCG 48/4885PRKCB 25/4885 |
| US-20260041660-A1 | Compositions And Methods for Treating Acute Respiratory Distress Syndrome (ARDS) And Inflammatory Disorders Caused by Corona Viruses and Other Respiratory Pathogens or Agents That Mediate Pulmonary Injury, Inflammation or Acute Respiratory Distress, And Related Compositions and Methods for Treating and Preventing Human SARS Coronavirus Infection, COVID-19 Disease and Related Symptoms | TSLP, MAVS, PLAA | PRKCA 32/4885PRKCG 102/4885PRKCB 115/4885 |
| US-12539289-B2 | Phorbol ester compositions and methods of use for treating or reducing the duration of cytopenia | MYD88, EBP, IL2 | PRKCA 45/4885PRKCG 154/4885PRKCB 37/4885 |
| US-20240358767-A1 | STEM CELL DIFFERENTIATION AND CHEMICAL COMPOUNDS | EBP, AKT3, PRKCD | PRKCA 11/4885PRKCG 24/4885PRKCB 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.